Clinical Trial Search

Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48 — 7.03; 6.06; 5.89 scores on a scale — p=0.0009

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown — 0; 75; 78 Participants…

Primary: Relative Pain Scores, as Measured by the Pain Numeric Rating Scale (NRS) — 3.87; 4.95 score on a scale

Primary: Change in Facial Wrinkles at 12 Weeks Post Final Treatment Compared to Baseline — -0.10 units on a scale

Primary: Maximum Observed Plasma Concentration (Cmax) of Plasma PF-07321332 — 1.886; 1.923 micrograms per milliliter (ug/mL)

Primary: Adjuvant Endocrine Therapy (AET) Medication Adherence — 77; 73; 71 percentage of prescribed doses taken

Primary: Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) Response at Week 16 — 13.8; 24.1; 34.5 percentage of participants

Primary: Residual Urine Volume — 62; 114; 48; 31 ml — p=0.84

Primary: Objective Response Rate (ORR) — 81 percentage of patients

Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…

Primary: New Opioid Discharge Prescriptions — 128; 28 Participants

Primary: Number of Subjects With POD1 Hemoglobin Less Than 10 g/dL — 97 Participants

Primary: Efficacy - Primary Endpoint During the Blinded Period — 50.0; 40.0; 60.0; 26.7 Percentage of participants — p== 0.2635

Primary: Shared Decision Making Conversations, as Measured by the Shared Decision Making Questionnaire (SDM-Q) — 5.14; 4.55 units on a scale